Drug Profile
Nimacimab - Bird Rock Bio
Alternative Names: JNJ 2463; Namacizumab; RYI-018Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Bird Rock Bio
- Class Anti-inflammatories; Antifibrotics; Gastrokinetics; Hepatoprotectants; Monoclonal antibodies; Obesity therapies; Urologics
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- No development reported Diabetic nephropathies; Non-alcoholic fatty liver disease
- Discontinued Diabetic gastroparesis; Obesity
Most Recent Events
- 09 Jan 2024 US FDA approves IND application to initiate a phase II clinical trial of nimacimab for obesity and chronic kidney disease
- 09 Jan 2024 Skye plans to initiate the phase II clinical trial in Obesity and Renal failure in mid-2024
- 11 Dec 2023 Skye Bioscience files an IND application with the US FDA in USA for obesity and chronic kidney disease